Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Soluble human complement receptor type 1 inhibits complement-mediated host defense

A J Swift1, T S Collins, P Bugelski

  • 1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-3923, USA.

Clinical and Diagnostic Laboratory Immunology
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Facilitating the use of routine data to evaluate artificial intelligence solutions: lessons from the NIHR/RCR data curation workshop.

Clinical radiology·2024
Same author

The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.

Clinical radiology·2020
Same author

Non-invasive methods for estimating mPAP in COPD using cardiovascular magnetic resonance imaging.

European radiology·2017
Same author

Commentary on: Survey of UK imaging practice for the investigation of pulmonary embolism in pregnancy.

Clinical radiology·2017
Same author

Response to: 'CT assessment for pulmonary hypertension requires systematic assessment of cardiac, vascular and parenchymal signs' by Marloes et al.

Thorax·2015
Same author

CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry.

Thorax·2014
Same journal

Longitudinal analysis of Severe Acute Respiratory Syndrome (SARS) coronavirus-specific antibody in SARS patients.

Clinical and diagnostic laboratory immunology·2005
Same journal

Immunoglobulin E binding reactivity of a recombinant allergen homologous to alpha-Tubulin from Tyrophagus putrescentiae.

Clinical and diagnostic laboratory immunology·2005
Same journal

Unidirectional suppression of Anaplasma phagocytophilum genotypes in infected lambs.

Clinical and diagnostic laboratory immunology·2005
Same journal

Long-term follow-up of Hepatitis B Surface antibody levels in subjects receiving universal Hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay.

Clinical and diagnostic laboratory immunology·2005
Same journal

Gamma interferon is dispensable for neopterin production in vivo.

Clinical and diagnostic laboratory immunology·2005
Same journal

Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51.

Clinical and diagnostic laboratory immunology·2005
See all related articles

Soluble complement receptor type 1 (sCR1) inhibits bacterial phagocytosis and host defense mechanisms. This suggests sCR1 may increase susceptibility to infections, impacting its therapeutic use.

Area of Science:

  • Immunology
  • Complement System Biology
  • Infectious Disease Research

Background:

  • Soluble complement receptor type 1 (sCR1) is a known inhibitor of complement activation.
  • sCR1 has potential therapeutic applications for complement-mediated disorders.
  • The impact of sCR1 on host defense against infection remains uninvestigated.

Purpose of the Study:

  • To investigate the effect of sCR1 on the host's ability to combat bacterial infections.
  • To determine if sCR1 interferes with complement-dependent and complement-independent bacterial clearance.

Main Methods:

  • In vitro experiments using human polymorphonuclear leukocytes and Streptococcus pneumoniae.
  • In vivo studies in rats involving sCR1 administration.
  • Assessment of serum hemolytic and opsonic activity in treated rats.

Related Experiment Videos

  • Determination of the 50% lethal dose (LD50) for bacterial pathogens in sCR1-treated rats.

    • Main Results:

    • sCR1 demonstrated a concentration-dependent inhibition of Streptococcus pneumoniae phagocytosis by human leukocytes.
    • sCR1 inhibited both complement-dependent opsonization and the ingestion of pre-opsonized bacteria.
    • In rats, sCR1 administration led to a dose-dependent reduction in serum hemolytic and opsonic activity.
    • sCR1 treatment significantly lowered the 50% lethal dose of S. pneumoniae and Pseudomonas aeruginosa in rats.

    Conclusions:

    • sCR1 significantly impairs complement-mediated host defense against bacterial infections.
    • The inhibitory effects of sCR1 on phagocytosis and opsonization suggest a potential increase in infection susceptibility.
    • These findings highlight a critical consideration for the therapeutic application of sCR1.